MELA Sciences Jumps 13.14% Ahead of Earnings (MELA)

Shares of MELA Sciences Inc. MELA are rallying higher this morning by 13.14%, trading at $6.33, after the company was mentioned in Barron's. Barron's said that shares a worth a look ahead of a FDA panel meeting, which could decide whether to recommend approval of a device from MELA that could revolutionize the way doctors screen patients for melanoma, one of the deadliest forms of skin cancer. They noted that a “yes” vote could double shares. MELA is scheduled to report earnings on November 16th. MELA Sciences, Inc., formerly Electro-Optical Sciences, Inc., is a medical device company focused on the design, development and commercialization of a non-invasive, point-of-care instrument to assist in the early diagnosis of melanoma. The company's product MelaFind, features a hand-held imaging device, which emits of light of multiple wavelengths to capture images of suspicious pigmented skin lesions and extract data.